Competitor Analysis: Heat shock protein 90 (Hsp90) Inhibitors

The present Competitive Intelligence report about Heat shock protein 90 (Hsp90) Inhibitors provides a competitor evaluation in the field of novel small molecules and antibodies targeting the heat shock protein 90 (Hspo90) chaperone for treatment of cancer as of July 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Inhibition of heat shock protein 90 (Hsp90) results in the degradation of oncoproteins that drive malignant progression, inducing cell death, making Hsp90 a target of substantial interest for cancer therapy. Over the last two to three decades, there has been dramatic progress in basic scientific understanding of the Hsp90 chaperone machinery and in the role of Hsp90 in malignancy. Structural and computational biology studies have recently provided important insights into underlying molecular mechanisms of Hsp90 function. By disabling multiple signal transduction pathways, Hsp90 inhibition provides a powerful therapeutic strategy in cancer research, which is selective for specific cancer mechanisms, yet broadly applicable to disparate tumors with different genetic signatures.

The report includes a compilation of current active projects in research and development of molecules targeting heat shock protein 90 (Hsp90). In addition, the report lists company-specific R&D pipelines of Hsp90 targeting small molecules and antibodies. Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.